MB, Levis & Associates’s Immunome IMNM Stock Holding History

MB, Levis & Associates’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$51K	Hold	2,373	–	–	0.02%	104
2026 Q2	$50.3K	Hold	2,373	–	–	0.02%	107
2026 Q1	$51.9K	Hold	2,373	–	–	0.02%	104
2025 Q4	$51K	Hold	2,373	–	–	0.02%	103
2025 Q3	$27.8K	Hold	2,373	–	–	0.01%	129
2025 Q2	$22.1K	Hold	2,373	–	–	0.01%	163
2025 Q1	$16K	Hold	2,373	–	–	0.01%	171
2024 Q4	$25.2K	Hold	2,373	–	–	0.01%	149
2024 Q3	$34.7K	Hold	2,373	–	–	0.02%	134
2024 Q2	$28.7K	Hold	2,373	–	–	0.02%	143
2024 Q1	$58.6K	Hold	2,373	–	–	0.03%	111
2023 Q4	$25.4K	Hold	2,373	–	–	0.01%	145
2023 Q3	$19.8K	Hold	2,373	–	–	0.01%	159
2023 Q2	$18.8K	Hold	2,373	–	–	0.01%	162
2023 Q1	$11.8K	Hold	2,373	–	–	0.01%	189
2022 Q4	$5.24K	Buy	+2,373	New	+$9.6K	﹤0.01%	206

Other funds holding IMNM

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Mitsubishi UFJ Asset Management (UK) London, United Kingdom $213M AUM 36.38% 1-Year Est. Return

Magnus Financial Group New York $1.5B AUM 16.47% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Maltin Wealth Management Ridgewood, New Jersey $308M AUM 16.5% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

MB, Levis & Associates's IMNM Position: Q3 2026 in Review

MB, Levis & Associates held its Immunome (IMNM) position steady in Q3 2026 at 2,373 shares worth $51K. The position accounts for 0.02% of the portfolio, ranked #104.

MB, Levis & Associates first reported a position in IMNM in Q4 2022 and has held it in 16 quarters since. The position peaked at $58.6K in Q1 2024. 17 funds tracked by Wall St. Rank hold IMNM as of Q3 2026.

MB, Levis & Associates held 2,373 shares of Immunome worth $51K as of Q3 2026.
MB, Levis & Associates left its Immunome share count unchanged in Q3 2026.
Immunome made up 0.02% of MB, Levis & Associates's portfolio in Q3 2026, its #104 holding.
MB, Levis & Associates first reported a position in Immunome in Q4 2022 and has held it in 16 quarters since.
MB, Levis & Associates's Immunome position peaked at $58.6K in Q1 2024.
17 funds tracked by Wall St. Rank held Immunome as of Q3 2026.

Based on MB, Levis & Associates's 13F filing for Q3 2026, filed 16 Oct 2026.